One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
From Survival to Stewardship: Delivering Hyperspecialized Cardiovascular Care at Scale
Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial
Some Much-Needed CONFIDENCE to Combat the Risk-Treatment Paradox in Chronic Kidney Disease
Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes
Impact of Early, Delayed, or Interrupted Treatment in Children With Familial Hypercholesterolemia
Emergency Encounters for Illness During and After the Los Angeles Wildfires
Adult Congenital Heart Disease: New Guidelines, Remaining Gaps, and Continual Opportunities
2025 Adults With Congenital Heart Disease Guideline From the Early-Career Perspective
Adapting the 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for Management of Adults With Congenital Heart Disease to Low Resource Settings
What Has Changed Since the First ACC/AHA Guidelines for the Management of Adult Congenital Heart Disease in 2008?
2025 ACC/AHA/HRS/ISACHD/SCAI Guideline Recommendations for the Treatment of Adult Congenital Heart Disease and Comparison With the 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
The Future of Adult Congenital Heart Care in the United States: Are We Keeping Up With the Pace of Progress?
2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
